Norspan (Buprenorphine)

Buprenorphine, the active ingredient in Norspan, is an opioid analgesic presented as a transdermal patch for transdermal use. It treats chronic moderate to severe pain requiring continuous opioid analgesia in adults.

GNH USA supplies Norspan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Buprenorphine is used in the management of chronic pain conditions that require continuous opioid therapy.

- Chronic cancer pain: provides steady analgesia over several days to improve quality of life. - Severe non‑cancer chronic pain: maintains consistent plasma levels for ongoing pain control. - Post‑surgical pain requiring prolonged opioid therapy: offers continuous delivery to reduce breakthrough pain.

Adverse reactions may occur with buprenorphine transdermal therapy.

Common Side Effects: - Nausea - Constipation - Headache - Skin irritation at the patch site

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Opioid dependence or withdrawal syndrome

When prescribing buprenorphine transdermal patches, consider the following precautions. - Assess opioid tolerance: confirm patient has adequate prior opioid exposure. - Monitor respiratory function: watch for signs of depression, especially after initiation. - Evaluate hepatic function: adjust use in patients with severe liver impairment. - Avoid abrupt discontinuation: taper to prevent withdrawal. - Use with caution in elderly patients: increased sensitivity to opioid effects. - Store at room temperature: keep patches in original pouch, protect from light and moisture.

Buprenorphine may interact with other medicines; awareness of interaction severity is essential.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines, alcohol): risk of profound sedation and respiratory depression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase buprenorphine levels. - Monoamine oxidase inhibitors (MAOIs): potential for hypertensive reactions.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Other opioids: additive analgesic effect and increased adverse events. - Serotonergic agents (e.g., SSRIs, tramadol): risk of serotonin syndrome.